Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Pharma market

905 views

Published on

Current scenario of Indian pharma market

  • Be the first to comment

Pharma market

  1. 1. PHARMA <ul><li>By </li></ul><ul><li>Deepak sahu </li></ul>
  2. 6. The Indian Patent Act <ul><li>The Indian Patent Act,1970 </li></ul><ul><ul><li>Process Patent </li></ul></ul><ul><ul><li>5 yrs. for Food, Drugs, Medicines, etc. & 14 yrs. for other inventions </li></ul></ul><ul><ul><li>Indian Market became undesirable to the MPCs </li></ul></ul><ul><ul><li>Focus on Generics and Neglect of New Drug Discovery </li></ul></ul><ul><ul><li>Development of Expertise in Reverse Engineering </li></ul></ul><ul><li>The Patent (Amendment) Act, 2005 </li></ul><ul><ul><li>Product Patent </li></ul></ul><ul><ul><li>20 yrs. for all inventions </li></ul></ul><ul><ul><li>Reversal of Law in case of violation of Patent from Plaintiff to Defendant </li></ul></ul><ul><ul><li>To recognize all patents filed after 1/1/05 </li></ul></ul><ul><ul><li>MPCs to enjoy same IPR in India as they enjoyed elsewhere </li></ul></ul><ul><ul><li>Shifting of focus from Generics to Innovative Drug Discovery </li></ul></ul>
  3. 7. GROWTH ENABLERS IPR ENFORCEMENT Accelerating Clinical Trials Increasing M&A Off shoring of R&D Activities Proven Prowess In Data Management Regulatory Reforms Fiscal Reforms
  4. 8. <ul><li>Off shoring of R&D Activities </li></ul><ul><li>Recognition of R&D as important growth driver by Indian companies </li></ul><ul><li>Increase in Investment in R&D Activities from 4% in 2004-05 to 7.7% in </li></ul><ul><li>2005-06 as a percentage of Sales </li></ul><ul><li>Low cost of doing R&D in India </li></ul><ul><li>Fiscal Reforms </li></ul><ul><li>Conferred Tax Deduction for expenses related to R&D </li></ul><ul><li>Reduced Interest Rates for Export financing </li></ul><ul><li>Reduction in Import Duties </li></ul><ul><li>Favorable economic environment for FDI in R&D </li></ul>
  5. 10. <ul><li>Accelerating Clinical Trials </li></ul><ul><li>Bridge between New Drug Discovery and New Drug Approval </li></ul><ul><li>Alone accounts for over 50% of the overall budget for the new </li></ul><ul><li>drug development </li></ul><ul><li>Large Patients pool with genetic diversity </li></ul><ul><li>Lower per patient cost of conducting trial in India </li></ul><ul><li>Clinical Research Outsourcing (CRO) Market stands at around Rs. 300 </li></ul><ul><li>crore and growing at 30% annually </li></ul><ul><li>Proven Prowess in Chemistry and Data Management </li></ul><ul><li>Abundance of highly trained and technically skilled clinical research </li></ul><ul><li>and medical professionals </li></ul><ul><li>Strong domestic capabilities in Data Management and IT </li></ul>
  6. 11. The Entry into Market
  7. 12. <ul><li>Increasing Mergers & Acquisitions </li></ul><ul><li>Rush of International Acquisitions by leading Indian Pharmaceutical Firms </li></ul><ul><li>Acquisitions intended to give Indian Drug Firms wide geographical </li></ul><ul><li>footprints </li></ul><ul><li>Some of the key acquisitions include (1) Dr. Reddy’s acquiring Betapharm, </li></ul><ul><li>a large German Generic player, & (2) Ranbaxy acquiring Terapia, largest </li></ul><ul><li>Generic company in Romania </li></ul><ul><li>Regulatory Reforms </li></ul><ul><li>Strengthening of Legal framework to curb production of spurious drugs </li></ul><ul><li>Formation of centralized National Drug Authority (NDA) </li></ul>
  8. 13. Future Outlook & Challenges <ul><li>Emergence of India as leading country in Global Pharmaceutical Market </li></ul><ul><li>Export to be the major thrust of the Industry </li></ul><ul><li>Evolving of Bio-pharmaceutical Market likely to emerge as one of the largest producer of Vaccines </li></ul><ul><li>Biotech Market estimated to reach $5 billion by 2010 </li></ul><ul><li>More Investment required in R&D </li></ul><ul><li>Fiscal Incentives for R&D should be provided on a long term basis of around 10 years </li></ul><ul><li>Clear Guidelines required on OTC Drugs </li></ul><ul><li>Higher Budget Outlay for Healthcare Services required </li></ul>
  9. 14. Thank You

×